GlaxoSmithKline plc EBITDA | GSK

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA GlaxoSmithKline plc

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
7.93 B	4.02 B	6.74 B	6.43 B	6.2 B	7.78 B	6.96 B	5.48 B	4.09 B	7.8 B	4.26 B	5.79 B	7.32 B	7.61 B	8.64 B

All numbers in GBP currency

Indicator range from annual reports

Maximum	Minimum	Average
8.64 B	4.02 B	6.47 B

Quarterly EBITDA GlaxoSmithKline plc

2025-Q4	2024-Q4	2023-Q4	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
7.93 B	4.02 B	6.74 B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in GBP currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.93 B	4.02 B	6.23 B

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	-22.6 M	-	-	-	Russia
Ayala Pharmaceuticals AYLA	-37.3 M	-	-	$ 7.46 M	Israel
Amryt Pharma plc AMYT	-38.6 M	-	-	$ 621 M	Britain
ASLAN Pharmaceuticals Limited ASLN	-43.7 M	-	-14.27 %	$ 1.7 M	Singapore
Revolution Medicines RVMD	-1.17 B	$ 207.32	0.24 %	$ 39.4 B	USA
Rhythm Pharmaceuticals RYTM	-192 M	$ 101.8	0.08 %	$ 6.62 B	USA
Rezolute RZLT	-79.9 M	$ 4.4	0.88 %	$ 334 M	USA
Sana Biotechnology SANA	-238 M	$ 3.45	0.77 %	$ 874 M	USA
Seer SEER	-72.9 M	$ 1.95	0.26 %	$ 108 M	USA
Precigen PGEN	-107 M	$ 6.87	0.14 %	$ 2.15 B	USA
SIGA Technologies SIGA	24.3 M	$ 3.2	1.86 %	$ 229 M	USA
Syndax Pharmaceuticals SNDX	-267 M	$ 19.94	0.05 %	$ 1.73 B	USA
Soligenix SNGX	-11.8 M	$ 0.38	1.18 %	$ 1.97 M	USA
Spruce Biosciences SPRB	-36.5 M	$ 59.09	2.0 %	$ 45.3 M	USA
Sarepta Therapeutics SRPT	-655 M	$ 20.94	0.04 %	$ 2.1 B	USA
Stoke Therapeutics STOK	-18.8 M	$ 30.05	0.81 %	$ 1.78 B	USA
Sutro Biopharma STRO	-151 M	$ 19.1	0.34 %	$ 162 M	USA
Shattuck Labs STTK	-47.8 M	$ 6.5	0.29 %	$ 452 M	USA
Supernus Pharmaceuticals SUPN	29.3 M	$ 42.43	0.23 %	$ 2.4 B	USA
Savara SVRA	-123 M	$ 5.53	2.98 %	$ 1.23 B	USA
China SXT Pharmaceuticals SXTC	-7.05 M	$ 2.24	0.45 %	$ 1.52 M	China
Takeda Pharmaceutical Company Limited TAK	343 B	$ 18.32	1.49 %	$ 28.9 B	Japan
Bio-Techne Corporation TECH	349 M	$ 72.31	0.01 %	$ 11.3 B	USA
Tenax Therapeutics TENX	-56.4 M	$ 1.98	2.06 %	$ 77.7 M	USA
Teva Pharmaceutical Industries Limited TEVA	3.16 B	$ 36.76	1.21 %	$ 42.1 B	Israel
TG Therapeutics TGTX	123 M	$ 55.74	0.58 %	$ 8.04 B	USA
Trevi Therapeutics TRVI	-49.2 M	$ 16.82	1.17 %	$ 2.27 B	USA
Taysha Gene Therapies TSHA	-109 M	$ 5.48	0.54 %	$ 1.75 B	USA
Sol-Gel Technologies Ltd. SLGL	-7.43 M	$ 69.37	0.35 %	$ 193 M	Israel
UroGen Pharma Ltd. URGN	-125 M	$ 43.82	0.02 %	$ 2.11 B	Israel
United Therapeutics Corporation UTHR	1.58 B	$ 497.97	2.12 %	$ 22.1 B	USA
Spero Therapeutics SPRO	6.31 M	$ 1.19	0.41 %	$ 66.7 M	USA
Scholar Rock Holding Corporation SRRK	-383 M	$ 57.42	3.78 %	$ 6.59 B	USA
Jounce Therapeutics JNCE	-50.2 M	-	-	$ 98.4 M	USA
NextCure NXTC	-55.4 M	$ 8.42	7.67 %	$ 23.9 M	USA
Verrica Pharmaceuticals VRCA	-12.1 M	$ 5.26	0.75 %	$ 56 M	USA
Viridian Therapeutics VRDN	-363 M	$ 23.17	1.09 %	$ 2.36 B	USA
Zosano Pharma Corporation ZSAN	-29.8 M	-	7.23 %	$ 2.72 M	USA
Vertex Pharmaceuticals Incorporated VRTX	4.38 B	$ 528.9	0.22 %	$ 135 B	USA
Verastem VSTM	-170 M	$ 8.08	0.55 %	$ 560 M	USA
vTv Therapeutics VTVT	-32.8 M	$ 32.79	0.03 %	$ 130 M	USA
Voyager Therapeutics VYGR	-128 M	$ 3.4	3.85 %	$ 200 M	USA
Aravive ARAV	-70 M	-	-13.39 %	$ 1.45 M	USA
Wave Life Sciences Ltd. WVE	-212 M	$ 4.91	1.03 %	$ 828 M	Singapore
Tonix Pharmaceuticals Holding Corp. TNXP	-124 M	$ 13.16	0.15 %	$ 112 M	USA
Xenetic Biosciences XBIO	-2.83 M	$ 4.28	0.86 %	$ 7.28 M	USA
XBiotech XBIT	-54 M	$ 2.18	0.23 %	$ 66.5 M	USA
Exicure XCUR	-3.99 M	$ 1.41	12.8 %	$ 8.88 M	USA
Xenon Pharmaceuticals XENE	-371 M	$ 59.55	0.18 %	$ 4.72 B	Canada
Xeris Pharmaceuticals XERS	26.2 M	$ 8.48	0.12 %	$ 1.36 B	USA